<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04160936</url>
  </required_header>
  <id_info>
    <org_study_id>Sad2007</org_study_id>
    <nct_id>NCT04160936</nct_id>
  </id_info>
  <brief_title>The Efficacy of Peritubal Analgesic Infiltration in Postoperative Pain Following Percutaneous Nephrolithotomy</brief_title>
  <official_title>The Effect of Peritubal Infiltration With Bupivacaine Around Nephrostomy Tract on Postoperative Pain Control After Percutaneous Nephrolithotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saddam Al Demour</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jordan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to investigate the effect of peritubal local anesthetic infiltration on
      pain scores and analgesic consumption in patients who underwent percutaneous nephrolithotomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators aim to investigate the effect of peritubal local anesthetic on pain scores
      and analgesic consumption in patients who underwent percutaneous nephrolithotomy. Patients
      aged between 18 and 65 years with renal stone &gt;2 cm will be included in this study .The
      patients will be divided into two groups. In Group A , the drug will be infiltrated to the
      renal capsule, perinephric fat, muscles, subcutaneous tissue, and skin under fluoroscopy with
      0.25 percent bupivacaine. This is a widely-used procedure by surgeons in the world. In Group
      B, no anesthetic will be infiltrated after the end of the procedure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 10, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>post operative pain: VAS</measure>
    <time_frame>1 week</time_frame>
    <description>Visual Analogue Scale (VAS), the patient is asked to describe the level of pain on a visual scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Renal Stone</condition>
  <arm_group>
    <arm_group_label>study group ,infiltration with 0.25% ropivacaine post-op</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At the end of the procedure ( surgery), In the patients of the study group, the 23-gauge, 90mm spinal needle will inserted up to the renal capsule under fluoroscopic guidance along the nephrostomy tube at 6 and 12 o'clock positions (cranial and caudal); then 20 ml of 0.25% bupivacaine will infiltrated into the nephrostomy tract, while gradually withdrawing the needle from renal capsule to the skin thereby infiltrating the renal capsule, perinephric fat, muscles, subcutaneous tissue and skin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group , no anesthesia infiltration post-op</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naropin Injectable Product</intervention_name>
    <description>following PCNL under general anesthesia, patients will receive Naropin local anesthetic infiltration</description>
    <arm_group_label>study group ,infiltration with 0.25% ropivacaine post-op</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20-70 years of age

          -  body mass index &lt;35,

          -  renal stone size &gt;2.0 cm.

        Exclusion Criteria:

          -  patients having supra-costal puncture.

          -  excessive intraoperative bleeding.

          -  renal stones requiring more than a single puncture.

          -  surgical procedure extending more than 3 hours.

          -  urinary tract infection.

          -  severe cardiopulmonary disease.

          -  abnormal renal function tests.

          -  allergy to local anesthetics.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Al Demour</last_name>
    <phone>00962799144000</phone>
    <email>saldemour@ju.edu.jo</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saddam Al Demour</name>
      <address>
        <city>Amman</city>
        <zip>11942</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saddam Al Demour</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Jordan</investigator_affiliation>
    <investigator_full_name>Saddam Al Demour</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

